Dr. Michael Stein is a cardiologist, well-published clinician scientist and experienced drug developer. He previously served as Vice President and Head of Study Medical Experts for Bayer Pharmaceuticals; Senior Director and Project Head of Clinical Development for Ikaria Biopharmaceuticals; Senior Director for Clinical Development at Novo Nordisk Pharmaceuticals; Senior Medical Director for Daiichi Sankyo; and Director of Cardiovascular Clinical Development at AstraZeneca. Dr. Stein has played key roles in bringing diverse therapies drugs to clinical practice including AZD6140/ticagrelor/Brilinta® and Prasugrel/Effient® for reducing clot formation in heart attack and stroke patients; Anti-TFPI antibody for improving coagulation in hemophilia patients; and IK5001 hydrogel for reduction or elimination of ventricular remodeling following large myocardial infarction.
Dr. Stein received his M.D. from the University of Illinois and fellowship training in cardiology and interventional cardiology at the University of Iowa. He has served on the medical faculties at the of Wisconsin College of Medicine and Emory University College of Medicine. His basic research efforts have focused on diverse aspects of cardiovascular physiology and pathophysiology.